IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.
Chicago-IntraLens Vision Inc. has changed its name to ReVision Optics Inc. (RVO) to align with its strategy to enter the presbyopia market.
“We feel our new name, ReVision Optics, perfectly suits both our corporate mission and our products. ReVision Optics will be targeting the refractive surgery market with an emphasis on the surgical correction of presbyopia via an intracorneal lens,” said J. Randy Alexander, president of ReVision Optics.
Alexander added that IntraLase Corp. has agreed to develop specialized software that will enable ReVision Optics to develop the collateral products to move forward in the marketplace. The software will enable ReVision Optics to produce two types of customized flaps that will assist eye surgeons to inject the company’s intracorneal lenses easily. The company’s lenses are undergoing clinical trial in the United States.
“While continuing to gain global market share of corneal flaps for LASIK, an integral part of our strategy is also to establish our laser as enabling technology for corneal applications which include corneal inlays, rings, and therapeutic procedures,” said Robert J. Palmisano, IntraLase president and chief executive officer.
As part of this agreement with ReVision, IntraLase will acquire full rights to the name IntraLens.
ReVision Optics will develop, manufacture, and market intracorneal lenses to correct and maintain vision. The lenses are made from a proprietary microporous hydrogel material and will be trademarked under the name PresbyLens.